RE: Some very simple questions31 Dec 2025 19:10
"Is this company just a scam to fool and fleece PIs?"
It does look that way. I bailed out 18 months ago because I became very bearish on fundraising for these pre-profitable biotechs. Ironically, that may finally be changing, but the problem with TRLS, in my opinion, is additionally that no matter how good the tech sounds to us lay people (which we all are frankly), the fact is no-one wants it enough to pay us meaningful amounts of money to deploy it. And 'meaningful' isn't a great deal of cash in the context of such a piddling enterprise, to keep TRLS on the road without capital raises.... and yet still no-one pays this to the co.
Sales progression isn't there. Big pharma are on the prowl for cheap biotechs with promising tech to fill up the gaps in their development pipelines and yet still no-one's come in for TRLS at a market cap of < £1m. Says something.
They told a good story - they always do - but on reflection it does feel a bit scammy.